{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:39:16Z","timestamp":1783982356005,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 19K17872"],"award-info":[{"award-number":["JP 19K17872"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clml.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T05:06:06Z","timestamp":1602219966000},"page":"e321-e327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-898X","authenticated-orcid":false,"given":"Ryujiro","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-7550","authenticated-orcid":false,"given":"Kaito","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinichiro","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iwazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7496-3518","authenticated-orcid":false,"given":"Mikio","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.10.004_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2017-09-772640","article-title":"Optimizing therapy in advanced-stage Hodgkin lymphoma","volume":"131","author":"Lim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.004_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14656566.2016.1127357","article-title":"Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments","volume":"17","author":"Oing","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2020.10.004_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","article-title":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma","volume":"11","author":"Thomas","year":"2020","journal-title":"J\u00a0Geriatr Onco"},{"key":"10.1016\/j.clml.2020.10.004_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.004_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","article-title":"Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era","volume":"61","author":"Taparra","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.004_bib6","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1080\/10428194.2017.1307980","article-title":"Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma","volume":"58","author":"Sun","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.004_bib7","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.004_bib8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.10.004_bib9","first-page":"35","article-title":"Bleomycin induced pulmonary toxicity in patients with germ cell tumours","volume":"22","author":"Usman","year":"2010","journal-title":"J\u00a0Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.clml.2020.10.004_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdg020","article-title":"Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours","volume":"14","author":"O\u2019Sullivan","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.10.004_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-018-1140-5","article-title":"Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors","volume":"35","author":"Maruyama","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2020.10.004_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.critrevonc.2012.12.003","article-title":"Revisiting bleomycin from pathophysiology to safe clinical use","volume":"87","author":"Froudarakis","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2020.10.004_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.clml.2020.10.004_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pupt.2018.07.002","article-title":"Use of animal models in IPF research","volume":"51","author":"Carrington","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.clml.2020.10.004_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2015.04.012","article-title":"Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions","volume":"97","author":"Della","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clml.2020.10.004_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.amjms.2016.11.021","article-title":"Comparative proteomic analysis of bleomycin-induced pulmonary fibrosis based on isobaric tag for quantitation","volume":"353","author":"Yang","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clml.2020.10.004_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/01.HYP.0000185149.56516.0a","article-title":"Does the angiotensin-converting enzyme (ACE)\/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension?","volume":"46","author":"Brosnihan","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.clml.2020.10.004_bib18","doi-asserted-by":"crossref","first-page":"109193","DOI":"10.1016\/j.biopha.2019.109193","article-title":"Exogenous angiotensin (1\u20137) directly inhibits epithelial-mesenchymal transformation induced by transforming growth factor-beta1 in alveolar epithelial cells","volume":"117","author":"Shao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clml.2020.10.004_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/JLB.MA1218-490RR","article-title":"Effect of preventive or therapeutic treatment with angiotensin 1-7 in a model of bleomycin-induced lung fibrosis in mice","volume":"106","author":"Rago","year":"2019","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2020.10.004_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fphys.2018.00180","article-title":"The selective angiotensin II type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary hypertension in an experimental model of bleomycin-induced lung injury","volume":"9","author":"Rathinasabapathy","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.clml.2020.10.004_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fphys.2018.00271","article-title":"rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling","volume":"9","author":"Rathinasabapathy","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.clml.2020.10.004_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/08923973.2018.1431924","article-title":"Valsartan attenuates bleomycin-induced pulmonary fibrosis by inhibition of NF-kappaB expression and regulation of Th1\/Th2 cytokines","volume":"40","author":"Mojiri-Forushani","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.clml.2020.10.004_bib23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/ars.2017.7261","article-title":"Autophagy attenuates angiotensin II-induced pulmonary fibrosis by inhibiting redox imbalance-mediated NOD-like receptor family pyrin domain containing 3 inflammasome activation","volume":"30","author":"Meng","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.clml.2020.10.004_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1159\/000443056","article-title":"ACE2 antagonizes VEGFa to reduce vascular permeability during acute lung injury","volume":"38","author":"Yu","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clml.2020.10.004_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1248\/bpb.b15-00358","article-title":"Osthole alleviates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2\/angiotensin-(1-7) axis and decreasing inflammation responses in rats","volume":"39","author":"Hao","year":"2016","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clml.2020.10.004_bib26","first-page":"027","article-title":"Bleomycin-induced neonatal lung injury requires the autocrine pulmonary angiotensin system","volume":"2","author":"Abdelwahab","year":"2016","journal-title":"Jacobs J Pulmonol"},{"key":"10.1016\/j.clml.2020.10.004_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/01902148.2014.963901","article-title":"MSCs with ACE II gene affect apoptosis pathway of acute lung injury induced by bleomycin","volume":"41","author":"Zhang","year":"2015","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.clml.2020.10.004_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430131","article-title":"Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice","volume":"36","author":"Wang","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clml.2020.10.004_bib29","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.3892\/mmr.2014.3025","article-title":"Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury","volume":"11","author":"Min","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.clml.2020.10.004_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/ars.2013.5818","article-title":"The angiotensin-converting enzyme 2\/angiotensin (1\u20137)\/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA\/Rho kinase pathway","volume":"22","author":"Meng","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.clml.2020.10.004_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1159\/000430393","article-title":"Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary endothelial cells during acute lung injury through suppressing MiR-4262","volume":"37","author":"Bao","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clml.2020.10.004_bib32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7150\/ijms.8365","article-title":"Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2\/angiotensin-(1\u20137) axis in rats","volume":"11","author":"Wu","year":"2014","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clml.2020.10.004_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-kappaB pathway","volume":"50","author":"Meng","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.clml.2020.10.004_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/01902148.2014.938200","article-title":"Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin","volume":"40","author":"Gao","year":"2014","journal-title":"Exp Lung Res"},{"key":"10.1016\/j.clml.2020.10.004_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.resinv.2012.12.005","article-title":"Preventive effect of irbesartan on bleomycin-induced lung injury in mice","volume":"51","author":"Tanaka","year":"2013","journal-title":"Respir Investig"},{"key":"10.1016\/j.clml.2020.10.004_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1164\/rccm.201205-0880OC","article-title":"Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models","volume":"187","author":"Shenoy","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clml.2020.10.004_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00109-012-0859-2","article-title":"Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury","volume":"90","author":"Rey-Parra","year":"2012","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.clml.2020.10.004_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1152\/ajplung.00009.2008","article-title":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.clml.2020.10.004_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1745-7254.2007.00493.x","article-title":"Early lung injury contributes to lung fibrosis via AT1 receptor in rats","volume":"28","author":"Chen","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clml.2020.10.004_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000090140","article-title":"Losartan attenuates bleomycin-induced pulmonary fibrosis in rats","volume":"73","author":"Yao","year":"2006","journal-title":"Respiration"},{"key":"10.1016\/j.clml.2020.10.004_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/thx.2005.051946","article-title":"Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis","volume":"61","author":"Molina-Molina","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.clml.2020.10.004_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4103\/IJPC.IJPC_107_19","article-title":"Bleomycin in Hodgkin\u2019s lymphoma - a boon or a bane? - a retrospective study of bleomycin pulmonary toxicity in Hodgkin\u2019s lymphoma","volume":"25","author":"Udupa","year":"2019","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.clml.2020.10.004_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.10.004_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1078155212444649","article-title":"Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman","volume":"19","author":"Ahmed","year":"2013","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2020.10.004_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40292-018-0290-z","article-title":"Hypertension management at older age: an update","volume":"26","author":"Del","year":"2019","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.clml.2020.10.004_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.phrs.2017.11.003","article-title":"Hypertension and cardiovascular risk: general aspects","volume":"129","author":"Kjeldsen","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clml.2020.10.004_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clml.2020.10.004_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1152\/ajplung.00273.2002","article-title":"Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo","volume":"284","author":"Li","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.clml.2020.10.004_bib49","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/10428194.2016.1236379","article-title":"Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma","volume":"58","author":"Falay","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.004_bib50","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/10428194.2016.1277387","article-title":"Early warning signs: FDG-PET to diagnose bleomycin toxicity","volume":"58","author":"Dickinson","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.10.004_bib51","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00277-008-0493-9","article-title":"Use of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in the early diagnosis of asymptomatic bleomycin-induced pneumonitis","volume":"87","author":"Connerotte","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.10.004_bib52","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.3324\/haematol.11856","article-title":"FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin\u2019s disease-a useful tool for monitoring pulmonary toxicity and disease activity","volume":"92","author":"Buchler","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.10.004_bib53","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/imj.13158","article-title":"Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP). The effect of pulmonary function testing on bleomycin dosing in germ cell tumours","volume":"46","author":"Roncolato","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2020.10.004_bib54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1078155215574294","article-title":"The role of screening and monitoring for bleomycin pulmonary toxicity","volume":"22","author":"Shippee","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T06:35:50Z","timestamp":1730529350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2152265020305565"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}